Nombre del producto:8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine

IUPAC Name:8-chloro-2-(methylsulfanyl)pyrimido[5,4-d][1,3]diazine

CAS:176637-10-8
Fórmula molecular:C7H5ClN4S
Pureza:95%+
Número de catálogo:CM167362
Peso molecular:212.66

Unidad de embalaje Stock disponible Precio($) Cantidad
CM167362-250mg in stock ǤȎư
CM167362-500mg in stock ʼnĽʼn
CM167362-1g in stock ĽŢĽ
CM167362-5g 1-2 Weeks Ǥůưư
CM167362-10g 1-2 Weeks ǵʼnưů

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :176637-10-8
Fórmula molecular:C7H5ClN4S
Punto de fusión:-
Código de sonrisas:CSC1=NC=C(N=CN=C2Cl)C2=N1
Densidad:
Número de catálogo:CM167362
Peso molecular:212.66
Punto de ebullición:
Nº Mdl:MFCD00227587
Almacenamiento:Store at 2-8°C.

Column Infos

Zongertinib
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients.
Zongertinib (also known as BI 1810631) is an investigational oral HER2-specific tyrosine kinase inhibitor (TKI) that is being developed as a potential treatment for HER2 mutated non-small cell lung cancer (NSCLC). Zongertinib was granted FDA Fast Track Designation in 2023, then in 2024 it was granted Breakthrough Therapy Designation by the U.S. FDA and China CDE for the treatment of adult patients with advanced NSCLC whose tumors have activating HER2 mutations, and who have received a prior systemic therapy.

Related Products